Main Article Content
The primary objective of this research was to investigate the antiurolithiatic effect of the aqueous Heartwood extract of Berberis asiatica (AEBA) on in vitro crystallization methods. The antiurolithiatic behaviour was carried out in the presence and absence of AEBA at the concentration range of 100-1000 μg/ml by employing crystal nucleation, crystal aggregation, and crystal growth assay methods. Standard drug Cystone was made use of positive control in the concentration range of 100-1000 μg/ml. Inhibition efficiency of AEBA on crystal nucleation, crystal aggregation and crystal growth was spectrophotometrically validated. The percentage inhibition rate of crystal nucleation, crystal aggregation and crystal growth by AEBA and standard drug cystone was endorsed to be dose-dependent in nature. The half maximal inhibitory concentration (IC50) values of standard drug cystone on crystal nucleation, crystal aggregation and crystal growth were estimated to be 415.30±21.35, 573.7±65.53 and 566.20±62.06 μg/ml, respectively, while the AEBA, IC50 values were reckoned to be 839±69.13, 927.10±69.98 and 851±86.60 μg/ml, respectively. The findings of in vitro crystallization study disclosed that an aqueous Heartwood extract of Berberis asiatica possesses calcium oxalate crystal inhibition activity on crystal nucleation, crystal aggregation, and crystal growth recommended it as a potent and promising antiurolithiatic activity.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.